USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
TECHNOVAX, INC.
Address:
765 OLD SAW MILL RIVER RD
TARRYTOWN, NY 10591-6702
Phone:
N/A
URL:
EIN:
142165292
DUNS:
361464907
Number of Employees:
6
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,610,042.00 2
SBIR Phase II $2,947,514.00 1

Award List:

Influenza Virus-like Particles As Vaccines

Award Year / Program / Phase:
2005 / SBIR / Phase I
Award Amount:
$1,010,042.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The long term objective of this proposal is to develop a novel cell-based system for creating influenza-virus like particle (VLP) vaccines against epidemic and potentially pandemic influenza viruses. This strategy will generate in a rapid and safe manner VLP… More

Development of Influenza Virus-Like Particle (VLP) Vaccines

Award Year / Program / Phase:
2009 / SBIR / Phase II
Award Amount:
$2,947,514.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Influenza virus-like particles (VLPs) have demonstrated in preclinical studies that they are highly immunogenic and efficacious in protecting against influenza infections. This emerging vaccine technology not only creat es new vaccine candidates with alternative… More

Software for improved accuracy and rapid tracking of kinematics from dynamic Xray

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
Jose M. Galarza – 914-345-2300
Abstract:
DESCRIPTION (provided by applicant): We propose to develop a broadly neutralizing, possibly universal influenza vaccine based on virus-like particles (VLPs) displaying remodeled HA molecules which present otherwise cryptic epitopes. These remodeled HAs will be expressed in forms lacking the dominant… More